<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252758</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-7-2010-01</org_study_id>
    <nct_id>NCT01252758</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma</brief_title>
  <official_title>A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of&#xD;
      albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol) and inhalation&#xD;
      grade lactose in a new dry powder delivery system called the Trivair deposition system.&#xD;
&#xD;
      Three different doses of albuterol sulfate DPI, TBS-7, will be administered in this dose&#xD;
      ranging clinical trial: an optimal dose, 80% of the optimal dose and 50% of the optimal dose&#xD;
      and will be compared with placebo and an active comparator.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forced expiratory volume at one second</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventolin HFA dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventolin HFA dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol sufate DPI (TBS-7) dose 1</intervention_name>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol sufate DPI (TBS-7) dose 2</intervention_name>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol sufate DPI (TBS-7) dose 3</intervention_name>
    <arm_group_label>albuterol sufate DPI (TBS-7) dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <arm_group_label>Ventolin HFA dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <arm_group_label>Ventolin HFA dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Generally healthy male or female subjects, over the age of 18. Females of child&#xD;
             bearing potential must be non-pregnant (confirmed by a negative serum hCG test at the&#xD;
             screening visit) or non-lactating.&#xD;
&#xD;
          2. Documented clinical history (minimum six months) of intermittent or mild persistent&#xD;
             asthma according to the Global Initiative for Asthma (GINA, 2009) criteria requiring&#xD;
             and responding to short acting inhaled b2-agonist (SABA) therapy.&#xD;
&#xD;
          3. Using a SABA alone, or concurrent use of anti-inflammatory therapy, (i.e. Singulair,®&#xD;
             theophylline or inhaled corticosteroid (ICS)). The dose and frequency of&#xD;
             anti-inflammatory medication should be stable for at least four weeks prior to the&#xD;
             screening visit. For subjects who are currently taking an ICS, the total daily dose&#xD;
             should not exceed 1000µg budesonide or equivalent steroid.&#xD;
&#xD;
          4. A pre-bronchodilator FEV1 ≥ 60% to 90% of predicted at screening.&#xD;
&#xD;
          5. Confirmed diagnosis of asthma by demonstrating: Reversibility of airway obstruction of&#xD;
             ≥ 12% increase in FEV1 within 30 minutes after the inhalation of a standard dose of&#xD;
             albuterol (2 puffs, 180 µg) delivered via pMDI.&#xD;
&#xD;
          6. Nonsmokers or ex-smokers (stopped at least 6-month period prior to the screening&#xD;
             visit).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A change in asthma mediation within the previous four weeks of screening visit.&#xD;
&#xD;
          2. A life-threatening asthma episode within the last six months or &gt; 2 within the past&#xD;
             year. A life-threatening asthma episode is defined as an asthma exacerbation which&#xD;
             required hospitalization and/or was associated with hypercapnia, respiratory arrest,&#xD;
             or hypoxic seizures.&#xD;
&#xD;
          3. If in the Investigator's opinion, the subjects asthma severity is too severe to&#xD;
             participate in the study, or they would be unable to withhold their asthma medication&#xD;
             for the times outlined above as well as require the use of daily high dose ICS&#xD;
             (&gt;1000µg budesonide or equivalent).&#xD;
&#xD;
          4. Use of a long acting inhaled b2-agonist (LABA), ipratropium bromide containing&#xD;
             medication (ie. Combivent) or Tiotropium therapy.&#xD;
&#xD;
          5. Use of any oral, depot or parental corticosteroids within four weeks of screening&#xD;
             visit. The use of topical corticosteroid cream (&lt;1%) to treat skin conditions is&#xD;
             allowed.&#xD;
&#xD;
          6. History of an upper or lower respiratory tract infection requiring antibiotics;&#xD;
             emergency room treatment in the preceding four weeks; or hospitalization in the&#xD;
             previous three months; or a history of multiple hospital visits for treatment of their&#xD;
             respiratory disease.&#xD;
&#xD;
          7. History of any immediate or delayed hypersensitivity reaction to inhaled b2-agonists,&#xD;
             lactose, milk-protein, or excipients (pMDI inhalers) any component of the&#xD;
             formulations.&#xD;
&#xD;
          8. Clinically significant history or current evidence of any of the diseases listed&#xD;
             below. Clinically significant is defined as any diseases that in the opinion of the&#xD;
             Investigator would put the subject at risk through study participation. These include,&#xD;
             but are not limited to:&#xD;
&#xD;
               -  bronchiectasis, bronchopulmonary dysplasia, cystic fibrosis, emphysema, chronic&#xD;
                  bronchitis, or other significant lung diseases&#xD;
&#xD;
               -  hypertension which, in the opinion of the Investigator, deems the subject unfit&#xD;
                  to enter the study; subjects must not have a persistent systolic pressure above&#xD;
                  145 mmHg or diastolic pressure above 85 mmHg unless the Investigator confirms&#xD;
                  that it is satisfactory for their age.&#xD;
&#xD;
               -  arrhythmias, coronary artery disease, congestive heart failure, congenital heart&#xD;
                  disease or other significant cardiac disease&#xD;
&#xD;
               -  diabetes mellitus requiring medication&#xD;
&#xD;
               -  cirrhosis, alcoholism, biliary obstruction or other hepatic disease&#xD;
&#xD;
               -  epilepsy, psychosis, or other conditions/diseases of the nervous system&#xD;
&#xD;
               -  malignancy&#xD;
&#xD;
               -  current or past history of glaucoma&#xD;
&#xD;
          9. Clinically significant ECG abnormalities.&#xD;
&#xD;
         10. History of seasonal allergic rhinitis that would require treatment during the study&#xD;
             period.&#xD;
&#xD;
         11. History of immunotherapy within six months of the screening visit or planned&#xD;
             initiation of immunotherapy within the study period. Subjects will be allowed to enter&#xD;
             the study if undergoing de-sensitization to a specific allergen for at least six&#xD;
             months on a stable maintenance dose prior to the screening visit. Seasonal pollen&#xD;
             de-sensitization therapy is allowed if this is not the initial course and no&#xD;
             significant adverse effect was observed with the previous administration.&#xD;
&#xD;
         12. Laboratory value exceeding the limit of normal and determined to be clinically&#xD;
             relevant by the Investigator.&#xD;
&#xD;
         13. Use of concomitant medications which might interfere with participation in the study&#xD;
             or the interpretation of data.&#xD;
&#xD;
         14. Current smokers.&#xD;
&#xD;
         15. Known or suspected history of alcohol drug or drug/solvent abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

